Skip to main content
SCYNEXIS INC logo

SCYNEXIS INC — Investor Relations & Filings

Ticker · SCYX ISIN · US8112922005 LEI · 529900XBHFGMNTU70154 US Manufacturing
Filings indexed 684 across all filing types
Latest filing 2018-11-13 Interim / Quarterly Rep…
Country US United States of America
Listing US SCYX

About SCYNEXIS INC

https://www.scynexis.com/

SCYNEXIS, Inc. is a biotechnology company focused on the discovery and development of novel anti-infectives to overcome difficult-to-treat and drug-resistant fungal infections. The company is pioneering a new class of broad-spectrum antifungal agents called 'fungerps,' which are triterpenoid-based compounds. These agents are being developed in both oral and intravenous formulations to treat a range of serious, invasive, and life-threatening fungal diseases, particularly those encountered in hospital environments. SCYNEXIS aims to address the significant global health threat of antifungal resistance by providing innovative therapeutic options where existing treatments are limited or ineffective. The company's development pipeline includes second-generation fungerp candidates.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q3 2018
2018-11-13 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-10-25 English
FORM 4 SUBMISSION
Director's Dealing
2018-10-03 English
8-K
Regulatory Filings
2018-09-21 English
Regulatory Filings 2018
Regulatory Filings
2018-09-17 English
424B3
Regulatory Filings
2018-09-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.